Inactive Instrument

PREDILIFE Stock Euronext Paris

ALPRE

FR0010169920

Biotechnology & Medical Research

End-of-day quote Euronext Paris
-	-

29/06	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
10/02	Intégrance Launches Preventive Health Program for Employees

News in other languages: PREDILIFE

17/07	Predilife : Bilan semestriel au 30/06/2026 du contrat de liquidité PREDILIFE
03/07	Predilife : RÉSILIATION DU CONTRAT DE LIQUIDITÉ CONCLU AVEC TSAF
02/07	Predilife : RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE
30/06	Un trimestre boursier exubérant, mais pas irrationnel ?
30/06	Predilife : PREDILIFE POINT CONCERNANT LA FDA ET MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

More news

Managers and Directors: PREDILIFE

Manager	Title	Age	Since
Stéphane Ragusa CEO	Chief Executive Officer	56	01/01/2004
Émilien Gauthier CTO	Chief Tech/Sci/R&D Officer	-	01/01/2007
Marion Renelier LAW	General Counsel	-	01/01/2016

Director	Title	Age	Since
Stéphane Ragusa CHM	Chairman	56	01/01/2004
Charles Vilgrain BRD	Director/Board Member	46	01/01/2018
Antoine Bricard BRD	Director/Board Member	58	01/01/2018

More insiders

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	4.03M 4.65M 4.65M 3.81M 3.45M 6.47M 446M 6.52M 45.42M 17.47M 226M 17.46M 17.07M 721M	P/E 2024	-3.18x	P/E 2025	-3.01x
Enterprise Value	8.8M 10.16M 10.16M 8.32M 7.54M 14.14M 975M 14.25M 99.33M 38.22M 494M 38.17M 37.33M 1.58B	EV / Sales 2024	34.5x	EV / Sales 2025	19.3x
Free-Float	48.75%	Yield 2024 *	-	Yield 2025	-

29/06	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
10/02	Intégrance Launches Preventive Health Program for Employees
10/10/25	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/07/25	Predilife S.A. announced a financing transaction	CI
06/06/25	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/04/25	Edil San Felice Bags EUR16 Million Maintenance Works Contract in Italy	MT
24/04/24	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/09/23	Predilife: a project accredited by Finance Innovation
15/07/23	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/04/23	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
12/04/23	Predilife: predictive assessment contract with Colas
29/10/22	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
25/04/22	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	CI

25/10/25	PREDILIFE : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025	PU
10/10/25	PREDILIFE : RESULTATS SEMESTRIELS 2025	PU
30/05/24	Predilife : PREDILIFE STRENGTHENS ITS ASSETS WITH THE ISSUANCE OF A PATENT FOR ITS AI METHOD	AT
01/05/24	Predilife : IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF EUR 25.07 REPRESENTS +391% POTENTIAL UPSIDE	AT
26/04/24	Predilife : Valuation of MammoRisk(R) software	AT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IOVANCE BIOTHERAPEUTICS, INC.	+1.08%	+7.59%	+312.33%	+77.61%	4.24B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+7.67%	+9.61%	+103.98%	+340.26%	4.26B
VERACYTE, INC.	-2.60%	-5.44%	+25.95%	+60.24%	3.23B
CAREDX, INC.	+0.52%	+4.63%	+275.46%	+564.65%	2.72B
BGI GENOMICS CO., LTD.	-0.98%	-2.52%	-31.65%	-31.64%	2.08B
FREENOME, INC.	-2.14%	-8.44%	+38.77%	-	1.57B
SEEGENE, INC.	+0.94%	+2.54%	+23.80%	+39.91%	1.08B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.92%	-4.31%	+152.94%	-34.23%	1.03B
CURIOX BIOSYSTEMS CO., LTD	+3.15%	+2.08%	-7.71%	+76.62%	620M
Average	+1.17%	-0.10%	+99.32%	+136.68%	2.31B
Weighted average by Cap.	+1.48%	+1.00%	+133.21%	+181.80%

	2024	2025
Net sales	493K 569K 569K 466K 422K 792K 54.62M 798K 5.57M 2.14M 27.69M 2.14M 2.09M 88.32M	836K 965K 965K 790K 716K 1.34M 92.56M 1.35M 9.43M 3.63M 46.93M 3.62M 3.54M 150M
Net income	-4.26M -4.92M -4.92M -4.03M -3.65M -6.85M -472M -6.9M -48.12M -18.51M -239M -18.49M -18.08M -764M	-3.93M -4.54M -4.54M -3.72M -3.37M -6.32M -436M -6.37M -44.4M -17.08M -221M -17.06M -16.68M -705M
Net Debt	3.54M 4.08M 4.08M 3.35M 3.03M 5.69M 392M 5.73M 39.93M 15.36M 199M 15.34M 15M 634M	4.78M 5.52M 5.52M 4.52M 4.09M 7.68M 529M 7.73M 53.91M 20.74M 268M 20.72M 20.26M 856M

PREDILIFE Stock Euronext Paris

Stocks

ALPRE

FR0010169920

Biotechnology & Medical Research

Valuation: PREDILIFE

Latest news: PREDILIFE

Press Releases: PREDILIFE

News in other languages: PREDILIFE

Managers and Directors: PREDILIFE

Bio Diagnostics & Testing

Financials

Company Profile